Revvity is a global scientific technology company focused on life sciences and diagnostics. The company originated from the decades-old PerkinElmer business and officially became Revvity in 2023 after separating its applied, food, and enterprise services businesses. Today, Revvity has moved beyond a traditional laboratory equipment company and developed into a broader life sciences platform covering drug discovery, genetic and cellular research, disease diagnostics, scientific software, and AI-powered research tools.
If you believe Revvity only sells laboratory instruments, you may be overlooking its deeper role in the global life sciences ecosystem. Developing a new medicine requires target discovery, cell testing, screening, data analysis, and validation, and Revvity provides products and software across many stages of this process. The company does not simply provide equipment; it helps researchers improve efficiency, analyze complex scientific data, and accelerate the development of new treatments.
Many investors initially view RVTY as a traditional life sciences tools company, but its strength comes from the combination of Life Sciences and Diagnostics. Its Life Sciences business supports pharmaceutical companies, biotechnology firms, and research institutions through solutions for cellular analysis, genetic research, and drug discovery, while its Diagnostics business provides disease testing and screening technologies. This structure allows Revvity to benefit from innovation-driven research while maintaining a stable foundation through diagnostic demand.
Artificial intelligence is becoming an important part of Revvity’s future development. Through its Signals AI platform, the company is integrating AI capabilities into scientific software, allowing researchers to better search, understand, and analyze complex research information. By combining AI with laboratory tools, cellular models, imaging technologies, and scientific data, Revvity is building a research workflow that connects prediction, experimentation, and analysis. Its expansion into areas such as human cell models, diabetes, obesity, and next-generation drug discovery further strengthens its position within emerging pharmaceutical research trends.
Financially, Revvity has shown improving operating performance. In the second quarter of 2026, the company generated approximately $730 million in revenue, while adjusted earnings per share reached $1.41 compared with $1.18 in the same period last year. Adjusted operating profit increased to approximately $211 million, and adjusted operating margin improved from 26.6% to 28.9%. The Diagnostics segment delivered particularly strong momentum, with comparable revenue growth of 12% and organic revenue growth of 11%. Management also continued optimizing the business structure by focusing resources on its core life sciences and diagnostics platforms.
Revvity’s market attention comes from its position at the intersection of several long-term trends: pharmaceutical innovation, precision diagnostics, scientific software, and AI-enabled research. The market often focuses on companies that successfully develop new medicines, but every breakthrough treatment requires thousands of experiments, analyses, and validation steps before reaching patients.
During a gold rush, the most consistent businesses are often not the ones searching for the largest discovery, but the ones providing the tools and technology that support everyone involved.
And Revvity is working to become that platform for the life sciences era by combining scientific tools, data capabilities, and artificial intelligence.